References
- Cai YG, Fang DC, Yang SM, et al (2004). [Increased expression of heparanase mRNA is correlated with metastasis of gastric carcinoma and is probably correlated with c-met protein]. Zhonghua Yi Xue Za Zhi, 84, 974-8.
- Chen JQ, Zhan WH, He YL, et al (2004a). Expression of heparanase gene, CD44v6, MMP-7 and nm23 protein and their relationship with the invasion and metastasis of gastric carcinomas. World J Gastroenterol, 10, 776-82. https://doi.org/10.3748/wjg.v10.i6.776
- Chen JQ, Zhan WH, He YL, et al (2004b). [Relationship between heparanase mRNA expression in human gastric cancer and its clinicopathological features]. Zhonghua Zhong Liu Za Zhi, 26, 609-11.
- Cheng C, Lu X, Wang G, et al (2010). Expression of SATB1 and heparanase in gastric cancer and its relationship to clinicopathologic features. APMIS, 118, 855-63. https://doi.org/10.1111/j.1600-0463.2010.02673.x
- Han Y, Xue XF, Shen HG, et al (2014). Prognostic significance of Beclin-1 expression in colorectal cancer: a meta-analysis. Asian Pac J Cancer Prev, 15, 4583-7. https://doi.org/10.7314/APJCP.2014.15.11.4583
- Inoue H, Mimori K, Utsunomiya T, et al (2001). Heparanase expression in clinical digestive malignancies. Oncol Rep, 8, 539-42.
- Liu WJ, Tan XH, Guo BP, et al (2013). Associations between RASSF1A promoter methylation and NSCLC: a metaanalysis of published data. Asian Pac J Cancer Prev, 14, 3719-24. https://doi.org/10.7314/APJCP.2013.14.6.3719
- Liu Y, Lv DL, Duan JJ, et al (2014). ALDH1A1 expression correlates with clinicopathologic features and poor prognosis of breast cancer patients: a systematic review and metaanalysis. BMC Cancer, 14, 444. https://doi.org/10.1186/1471-2407-14-444
- Masola V, Secchi MF, Gambaro G, et al (2014). Heparanase as a target in cancer therapy. Curr Cancer Drug Targets, 14, 286-93. https://doi.org/10.2174/1568009614666140224155124
- McShane LM, Altman DG, Sauerbrei W, et al (2006). REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat, 100, 229-35. https://doi.org/10.1007/s10549-006-9242-8
- Nadir Y, Brenner B (2014). Heparanase multiple effects in cancer. Thromb Res, 133 Suppl 2, 90-4.
- Naomoto Y, Takaoka M, Okawa T, et al (2005). The role of heparanase in gastrointestinal cancer (Review). Oncol Rep, 14, 3-8.
- Pisano C, Vlodavsky I, Ilan N, et al (2014). The potential of heparanase as a therapeutic target in cancer. Biochem Pharmacol, 89, 12-9. https://doi.org/10.1016/j.bcp.2014.02.010
- QIN S-y, JIANG H-x, LI X (2007). Significance of bFGF, FGFR-2 and Hpa expression in gastric precancerous lesions and gastric carcinoma tissues. Chinese J Practical Internal Med, 17, 025.
- REN X-l, ZHU R-z, WANG L-j (2003). Clinicopathological significance of heparanase mRNA expression in gastric carcinoma. Chinese J Exp Surg, 9, 006.
- Takaoka M, Naomoto Y, Ohkawa T, et al (2003). Heparanase expression correlates with invasion and poor prognosis in gastric cancers. Lab Invest, 83, 613-22. https://doi.org/10.1097/01.LAB.0000067482.84946.BD
- Tang W, Nakamura Y, Tsujimoto M, et al (2002). Heparanase: a key enzyme in invasion and metastasis of gastric carcinoma. Mod Pathol, 15, 593-8. https://doi.org/10.1038/modpathol.3880571
- Wang Z, Xu H, Jiang L, et al (2005). Positive association of heparanase expression with tumor invasion and lymphatic metastasis in gastric carcinoma. Mod Pathol, 18, 205-11. https://doi.org/10.1038/modpathol.3800282
- Wu BW, Li DF, Ke ZF, et al (2010). Expression characteristics of heparanase in colon carcinoma and its close relationship with cyclooxygenase-2 and angiogenesis. Hepatogastroenterol, 57, 1510-4.
- Xi Y, Zhang Y, Qi YJ, et al (2009). Expression of heparanase and CD105 in stomach neoplasm and its correlation. J Henan University, 3, 010.
- Zhang J, Yang J, Han X, et al (2012). Overexpression of heparanase multiple antigenic peptide 2 is associated with poor prognosis in gastric cancer: Potential for therapy. Oncol Lett, 4, 178-82. https://doi.org/10.3892/ol.2012.703
- Zhang X, Xu S, Tan Q, et al (2013). High expression of heparanase-2 is an independent prognostic parameter for favorable survival in gastric cancer patients. Cancer Epidemiol, 37, 1010-3. https://doi.org/10.1016/j.canep.2013.09.012
- Zheng L, Jiang G, Mei H, et al (2010). Small RNA interferencemediated gene silencing of heparanase abolishes the invasion, metastasis and angiogenesis of gastric cancer cells. BMC Cancer, 10, 33. https://doi.org/10.1186/1471-2407-10-33
- Zheng L, Weng M, Qi M, et al (2012). Aberrant expression of intelectin-1 in gastric cancer: its relationship with clinicopathological features and prognosis. J Cancer Res Clin Oncol, 138, 163-72. https://doi.org/10.1007/s00432-011-1088-8
- Zheng LD, Jiang GS, Pu JR, et al (2009). Stable knockdown of heparanase expression in gastric cancer cells in vitro. World J Gastroenterol, 15, 5442-8. https://doi.org/10.3748/wjg.15.5442
- Cai YG, Fang DC, Yang ShM, et al (2004). The significance of the expression of heparanase mRNA in gastric cancer tissues. J Fourth Military Med University, 909-11.
- Chen Bo (2009). Expressions of heparanase and matrix metalloproteinase-9 in gastric cancer and its clinical significance. J Hainan Med College, 852-4
- Huang ZHQ, Liu SH, Chen SL, et al (2008). The study of HPA, bFGF and FGFR-2 expressions in gastric cancer tissue. J Modern Chinese Western Integrated Med. 3565, 6-75.
- Jiang WH, Zhu XM, Yang ZHP, et al (2011). The expression of heparanase in gastric cancer tissue with its clinical pathological features. Chinese J Gerontol, 3262-3.
- Li Tao, QJ (2012). The expression and significance of integrin alpha 5 beta 1 and heparanase in gastric carcinoma. Guangdong Med. 2974-6.
- Liang H, Zhang L, Zhang Xu (2009). The expression and clinical significance of HPA in gastric cancer tissues. Health Vocational Educat, 102-3.
- Liu Y, Yang HG, Zuo LF (2007). The expression of heparanase in gastric cancer and DNA content quantitative research by flow cytometry. J Med Res, 40-3.
- Liu ZH, An ZhQ, Li EJ, et al (2004). The expressions of heparanase, bFGF fibroblast growth factor expression in gastric cancer with their effects on angiogenesis and tumor progression. Sichuan J Physiological Sci 106-8.
- Ma XM, Sun Q, Ren MJ, et al (2007). The expressions of heparanase and NF kappa B in gastric cancer and with the clinical pathological features and vascular formation. J China Histochemistry Cytochemistry, 12-8.
- Qi YQ, Si JL, Li WL, et al (2010). The expressions of Syndecan-1 and HPA-1 mRNA in gastric cancer tissue and its relationship with invasion and metastasis of gastric cancer. Chinese J Cancer, 110-5.
- Ru GQ, Zhao ZHS, Tang QL, et al (2006). The mRNA expressions of Syndecan-1 and heparanase in gastric cancer and its relationship with metastasis and prognosis of gastric cancer. Chinese J Surg, 1062-4.
- Su N, Chen B, Chen JZH, et al (2009). The expression of heparanase in gastric cancer and hepatocellular carcinoma and its clinical significance. J Practical Med, 1207-9.
- Sun YS, Ye ZY, a randomised (2005). The expression of heparanase protein in gastric cancer and its clinical significance. Zhejiang Med J, 644, 5-9.
- Wang ZhH, Wang YH, Jiang FT, et al (2008). The expressions and significances of heparanase in gastric cancer, paracancerous tissues and normal gastric tissue. Modern Med Oncol, 1953-5.
- Zhang L, Zhang X, Yang AJ, et al (2009). The expressions and significances of HPA and HIF-1 in gastric cancer. Shandong J Med Pharmcol, 89-90.
- Zheng ZHC, Wang SHB, Xu HM (2004). The expressions of heparanase and bFGF in gastric cancer and its relationship with invasion and metastasis of gastric cancer. Chinese J Clin Oncol, 31, 4-8.
Cited by
- Oleuropein represses the radiation resistance of ovarian cancer by inhibiting hypoxia and microRNA-299-targetted heparanase expression vol.8, pp.8, 2017, https://doi.org/10.1039/C7FO00552K
- MicroRNA-1258: An invasion and metastasis regulator that targets heparanase in gastric cancer vol.13, pp.5, 2017, https://doi.org/10.3892/ol.2017.5886